All In Biotech

Drug Trial Radar · NCT04901689

Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation

A Phase 3, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Leronlimab in Combination With Standard of Care for Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation

Last checked: Nov 19, 2026Latest source record: Apr 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

SuspendedPivotal-lookingPhase 3. Randomized with 316 participants. This is a heuristic, not a regulatory label.

Status

Suspended

Enrollment

316

Planned (sponsor's estimate)

Start

Oct 23, 2021

Primary completion

Feb 2023

Study completion Feb 2023

Sponsor

Lead sponsor
Hospital Israelita Albert EinsteinAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
CytoDyn, Inc.
First posted
May 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Leronlimab (PRO 140) is a humanized IgG4,k monoclonal antibody (mAb) that recognizes the C-C chemokine receptor type 5 (CCR5). Disruption of the C-C chemokine ligand 5 (CCL5)-CCR5 axis via leronlimab-mediated CCR5 blockade might prevent pulmonary trafficking of pro-inflammatory leukocytes and dampen pathogenic immune activation in coronavirus disease 2019 (COVID-19). The purpose of the study is to assess the safety and efficacy of leronlimab plus standard of care in critically ill patients hospitalized with COVID-19 pneumonia who are requiring mechanical ventilation or extracorporeal oxigenation (ECMO).

Conditions

  • COVID-19 Pneumonia

Interventions

  • LeronlimabDrug

    Leronlimab 700 mg

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative proportion of clinical recoveryTime frame: 28 days

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Israelita Albert Einstein

    São Paulo, Brazil

  • Hospital M'Boi Mirim

    São Paulo, Brazil

  • Hospital Dr Jayme dos Santos Neves

    Laranjeiras, Espírito Santo, Brazil

  • Clinica São Roque

    Ipiaú, Estado de Bahia, Brazil

  • Santa Casa de Misericórdia da Bahia - Hospital Santa Izabel

    Salvador, Estado de Bahia, Brazil

  • Hospital do Coração do Brasil

    Brasília, Federal District, Brazil

  • Santa Casa de Misericórdia de Passos

    Passos, Minas Gerais, Brazil

  • Hospital 9 de Julho

    São Paulo, Please Select, Brazil

  • Hospital São Lucas Copacabana

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Instituto Atena de Pesquisa Clínica

    Natal, Rio Grande do Norte, Brazil

  • Hospital São Vicente de Paulo

    Passo Fundo, Rio Grande do Sul, Brazil

  • Hospital Mãe de Deus

    Porto Alegre, Rio Grande do Sul, Brazil

  • Irmandade da Santa Casa de Misericórdia Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Fundação PIO XII

    Barretos, São Paulo, Brazil

  • Irmandade do Sr. Bom Jesus dos Passos da Santa Casa de Misericórdia de Bragança Paulista

    Bragança Paulista, São Paulo, Brazil

  • Instituto de Pesquisa Clínica de Campinas

    Campinas, São Paulo, Brazil

  • Hospital Santa Ignes

    Indaiatuba, São Paulo, Brazil

  • Fundação Faculdade Regional de Medicina de São José do Rio Preto

    São José do Rio Preto, São Paulo, Brazil

  • BP Mirante

    São Paulo, São Paulo, Brazil

  • Hospital Alemão Oswaldo Cruz

    São Paulo, São Paulo, Brazil

  • Hospital Beneficência Portuguesa

    São Paulo, São Paulo, Brazil

  • Santa Casa de Votuporanga

    Votuporanga, São Paulo, Brazil

  • Centro de Pesquisa Clínica do Coração

    Aracaju, Sergipe, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.